Modified BuShenYiQi formula alleviates experimental allergic asthma in mice by negative regulation of type 2 innate lymphoid cells and CD4+ type 9 helper T cells and the VIP–VPAC2 signalling pathway
Context Modified BuShenYiQi formula (M-BYF) is derived from BuShenYiQi formula, used for the treatment of allergic asthma. The exact effect and mechanism of M-BYF on the improvement of asthma remain unclear. Objective We investigated the mechanism underlying the therapeutic effect of M-BYF on allerg...
Main Authors: | Muhua Huang, Jinfeng Wu, Jingcheng Dong |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | Pharmaceutical Biology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/13880209.2021.1970198 |
Similar Items
-
BuShenYiQi granule inhibits atopic dermatitis via improving central and skin Hypothalamic-Pituitary-Adrenal axis function.
by: Lingwen Kong, et al.
Published: (2015-01-01) -
Correction: BuShenYiQi Granule Inhibits Atopic Dermatitis via Improving Central and Skin Hypothalamic -Pituitary -Adrenal Axis Function.
by: Lingwen Kong, et al.
Published: (2015-01-01) -
Bu-Shen-Yi-Qi formula ameliorates airway remodeling in murine chronic asthma by modulating airway inflammation and oxidative stress in the lung
by: Jie Cui, et al.
Published: (2019-04-01) -
RNA-Seq Expression Analysis of Chronic Asthmatic Mice with Bu-Shen-Yi-Qi Formula Treatment and Prediction of Regulated Gene Targets of Anti-Airway Remodeling
by: Jie Cui, et al.
Published: (2021-01-01) -
QiShenYiQi Attenuates Renal Interstitial Fibrosis by Blocking the Activation of β-Catenin.
by: Zhanmei Zhou, et al.
Published: (2016-01-01)